The Contrary Investment Case: 3 Reasons To Stock Up On AstraZeneca plc

Royston Wild looks at why AstraZeneca plc (LON: AZN) could be a canny share purchase.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.


In recent days I have looked at why I believe AstraZeneca (LSE: AZN) (NYSE: AZN.US) could be a dangerous stock selection.

But, of course, the world of investing is never a black and white business — it takes a variety of views to make a market, and the actual stock price is the only indisputable factor. With this in mind I’m going to lay out the key factors which could, in fact, push demand for AstraZeneca through the roof.

Restructuring improves long-term earnings picture

AstraZeneca’s revenues have been hammered in recent years as the effect of patent expirations across key products has seen the competition chip away at earnings. And the company has warned that further sales weakness is expected to crimp earnings again this year, because AstraZeneca’s timeline in combating the loss of exclusivity by developing new drugs has lagged significantly behind that of its rivals.

Still, for long-term investors the company’s ongoing R&D transformation package creates a much more promising outlook for its beleaguered pipeline. Not only is the firm investing heavily in creating a network of laboratories across the US, UK and Sweden in red-hot  bioscience regions, but it’s also busy on the M&A trail, aiming to boost its development capabilities.  

Emerging markets streaking away

A positive point in AstraZeneca’s woeful revenues performance over the past year, however, has been the progress it’s making in critical emerging markets, another crucial factor for growth in coming years. Group revenues from developing regions increased 6% last year, the company noted, driven by sales advances in China and South Korea, which leapt 21% and 17% respectively.

And AstraZeneca is ramping up its exposure to developing regions through acquisition activity — the firm’s purchase of Bristol-Myers Squibb‘s holding in their joint diabetes venture last month gives the company improved reach in these high growth regions, for example.

Still a meaty dividend selection

AstraZeneca elected to keep the dividend on hold for the second consecutive year, at 280 cents per share, as earnings weakness worsened. However, City analysts expect the company to get its progressive payout policy back on track from this year, as its product pipeline steadily improves earnings, at least during the medium term.

The pharma giant is anticipated to lift the full-year dividend 1.8% this year to 285.1 cents, with an additional 0.6% advance pencilled in for this year to 286.7 cents. These rises represent a shadow of the annual hikes seen in previous years, although such projections still create a yield of 4.2%, far ahead of the 3.2% FTSE 100 forward average.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston does not own shares in AstraZeneca.

More on Investing Articles

Warren Buffett at a Berkshire Hathaway AGM
US Stock

This growth stock that Warren Buffett owns just hit 52-week lows. Should I buy?

Jon Smith flags up a high-profile US stock that the great Warren Buffett bought back in 2020 but which has…

Read more »

White female supervisor working at an oil rig
Investing Articles

Could the UK general election be bad news for this FTSE 250 energy producer?

The country is due to vote in the general election on 4 July. Our writer looks at the possible implications…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Should we buy cheap FTSE 100 shares now, before it’s too late?

The FTSE 100 is up 5% so far in 2024 and hit an all-time high in May. That means the…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

Here’s why I think the Lloyds share price could hit a 5-year high in 2024

It's up 13.5% so far in 2024, and reaching new highs. But where might the Lloyds Bank share price go…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

If I’d put £15k into this FTSE 250 stock in 2008, I’d have over £1.26m today

This multi-billion-pound business has created plenty of millionaires over the last 16 years, but can it repeat this performance?

Read more »

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

3 dividend shares I’ve bought for the next decade!

I think these UK dividend shares can amplify my long-term passive income, and could even be on track to becoming…

Read more »

Investing Articles

If I’d put £5,000 in Scottish Mortgage shares at the start of 2024, here’s what I’d have now

Scottish Mortgage shares have staged a recovery lately, powered by the public and private growth stocks held in the portfolio.

Read more »

Happy couple showing relief at news
Investing Articles

9.9% dividend yield! Is this FTSE 100 stock a brilliant bargain?

This leading British enterprise looks like a delicious deal for passive income, trading at a low multiple while offering a…

Read more »